OBJECTIVES: The aim of this study was to test whether c-Src tyrosine kinase mediates connexin-43 (Cx43) reduction and sudden cardiac death in a transgenic mouse model of cardiac-restricted overexpression of angiotensin-converting enzyme (ACE8/8 mice). BACKGROUND: Renin-angiotensin system activation is associated with an increased risk for arrhythmia and sudden cardiac death, but the mechanism is not well understood. The up-regulation of c-Src by angiotensin II may result in the reduction of Cx43, which impairs gap junction function and provides a substrate for arrhythmia. METHODS: Wild-type and ACE8/8 mice with and without treatment with the c-Src inhibitor 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) were studied. Telemetry monitoring, in vivo electrophysiologic studies, Western blot analyses for total and phosphorylated c-Src and Cx43, immunohistochemistry staining for Cx43, and functional assessment of Cx43 with fluorescent dye diffusion were performed. RESULTS: The majority of the arrhythmic deaths resulted from ventricular tachycardia degenerating to ventricular fibrillation (83%). Levels of total and phosphorylated c-Src were increased and Cx43 reduced in ACE8/8 mice. PP1 reduced total and phosphorylated c-Src levels, increased Cx43 level by 2.1-fold (p < 0.005), increased Cx43 at the gap junctions (immunostaining), improved gap junctional communication (dye spread), and reduced ventricular tachycardia inducibility and sudden cardiac death. The survival rate increased from 11% to 86% with 4 weeks of PP1 treatment (p < 0.005). Treatment with an inactive analog did not change survival or Cx43 levels. CONCLUSIONS: Renin-angiotensin system activation is associated with c-Src up-regulation, Cx43 loss, reduced myocyte coupling, and arrhythmic sudden death, which can be prevented by c-Src inhibition. This suggests that an increase in c-Src activity may help mediate renin-angiotensin system-induced arrhythmias and that c-Src inhibitors might exert antiarrhythmic activity.
OBJECTIVES: The aim of this study was to test whether c-Src tyrosine kinase mediates connexin-43 (Cx43) reduction and sudden cardiac death in a transgenic mouse model of cardiac-restricted overexpression of angiotensin-converting enzyme (ACE8/8 mice). BACKGROUND: Renin-angiotensin system activation is associated with an increased risk for arrhythmia and sudden cardiac death, but the mechanism is not well understood. The up-regulation of c-Src by angiotensin II may result in the reduction of Cx43, which impairs gap junction function and provides a substrate for arrhythmia. METHODS: Wild-type and ACE8/8 mice with and without treatment with the c-Src inhibitor 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) were studied. Telemetry monitoring, in vivo electrophysiologic studies, Western blot analyses for total and phosphorylated c-Src and Cx43, immunohistochemistry staining for Cx43, and functional assessment of Cx43 with fluorescent dye diffusion were performed. RESULTS: The majority of the arrhythmic deaths resulted from ventricular tachycardia degenerating to ventricular fibrillation (83%). Levels of total and phosphorylated c-Src were increased and Cx43 reduced in ACE8/8 mice. PP1 reduced total and phosphorylated c-Src levels, increased Cx43 level by 2.1-fold (p < 0.005), increased Cx43 at the gap junctions (immunostaining), improved gap junctional communication (dye spread), and reduced ventricular tachycardia inducibility and sudden cardiac death. The survival rate increased from 11% to 86% with 4 weeks of PP1 treatment (p < 0.005). Treatment with an inactive analog did not change survival or Cx43 levels. CONCLUSIONS: Renin-angiotensin system activation is associated with c-Src up-regulation, Cx43 loss, reduced myocyte coupling, and arrhythmic sudden death, which can be prevented by c-Src inhibition. This suggests that an increase in c-Src activity may help mediate renin-angiotensin system-induced arrhythmias and that c-Src inhibitors might exert antiarrhythmic activity.
Authors: R Aikawa; I Komuro; T Yamazaki; Y Zou; S Kudoh; M Tanaka; I Shiojima; Y Hiroi; Y Yazaki Journal: J Clin Invest Date: 1997-10-01 Impact factor: 14.808
Authors: E J Wojcik; S Sharifpoor; N A Miller; T G Wright; R Watering; E A Tremblay; K Swan; C R Mueller; B E Elliott Journal: Oncogene Date: 2006-05-04 Impact factor: 9.867
Authors: Vijaykumar S Kasi; Hong D Xiao; Lijuan L Shang; Shahriar Iravanian; Jonathan Langberg; Emily A Witham; Zhe Jiao; Carlos J Gallego; Kenneth E Bernstein; Samuel C Dudley Journal: Am J Physiol Heart Circ Physiol Date: 2007-03-02 Impact factor: 4.733
Authors: A G Reaume; P A de Sousa; S Kulkarni; B L Langille; D Zhu; T C Davies; S C Juneja; G M Kidder; J Rossant Journal: Science Date: 1995-03-24 Impact factor: 47.728
Authors: Raul R Blanco; Harland Austin; Richard N Vest; Ravinder Valadri; Wei Li; Bernard Lassegue; Qing Song; Barry London; Samuel C Dudley; Heather L Bloom; Charles D Searles; A Maziar Zafari Journal: J Card Fail Date: 2012-08-09 Impact factor: 5.712
Authors: Wael A AlJaroudi; Marwan M Refaat; Robert H Habib; Laila Al-Shaar; Madhurmeet Singh; Rebecca Gutmann; Heather L Bloom; Samuel C Dudley; Patrick T Ellinor; Samir F Saba; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Indrani Halder; Barry London Journal: Am J Cardiol Date: 2015-01-15 Impact factor: 2.778
Authors: Sabine Huke; Raghav Venkataraman; Michela Faggioni; Sirish Bennuri; Hyun S Hwang; Franz Baudenbacher; Björn C Knollmann Journal: Circ Res Date: 2013-03-26 Impact factor: 17.367
Authors: Cody A Rutledge; Fu Siong Ng; Matthew S Sulkin; Ian D Greener; Artem M Sergeyenko; Hong Liu; Joanna Gemel; Eric C Beyer; Ali A Sovari; Igor R Efimov; Samuel C Dudley Journal: J Am Coll Cardiol Date: 2014-01-08 Impact factor: 24.094